Core Viewpoint - Becton, Dickinson and Company (NYSE:BDX) is recognized as one of the 13 cheapest Dividend Aristocrats to invest in, indicating its strong dividend history and potential value in the market [1]. Financial Performance - For fiscal Q1 2026, the company reported revenue of $5.3 billion, reflecting a 0.4% overall growth and a 2.5% growth within the New BD segment [4]. - Adjusted gross margin increased to 53.4%, and adjusted EPS was reported at $2.91, both exceeding internal forecasts [4]. Strategic Developments - The company is set to finalize the combination of its Life Sciences unit with Waters Corporation through a Reverse Morris Trust transaction, which is expected to generate a $4 billion cash distribution [5]. - Of the $4 billion, $2 billion is earmarked for share repurchases and the remaining $2 billion for debt reduction, aligning with BD's focused capital allocation strategy [5]. - CEO Thomas Polen introduced a strategic agenda called "Excellence Unleashed," aimed at enhancing competitiveness, accelerating innovation, and ensuring consistent execution [6]. Leadership Changes - During the earnings call, CEO Thomas Polen announced Shawn Bevec as the new Senior Vice President of Investor Relations, indicating a focus on strengthening investor communications [3]. Market Position - Becton, Dickinson operates as a global medical technology company, providing medical supplies, devices, laboratory equipment, and diagnostic products to various healthcare sectors [7].

Core Insights - Becton Dickinson and Co. (BDX) is a leading global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents, operating through three segments: BD Medical, BD Life Sciences, and BD Interventional [1] Financial Performance - On February 10, 2026, BDX executed a stock split with a ratio of 125 for 159, aimed at making shares more affordable [2][4] - BDX reported first-quarter 2026 adjusted earnings of $2.91 per share, exceeding the consensus estimate of $2.81, with sales reaching $5.25 billion, slightly above the expected $5.15 billion [2][4] Strategic Changes - BDX is undergoing significant changes, including the separation of its Biosciences and Diagnostic Solutions businesses and a combination with Waters Corporation [3] - The company has lowered its fiscal 2026 adjusted earnings guidance from a range of $14.75-$15.05 per share to $12.35-$12.65 per share, compared to the consensus of $14.72, indicating a transition year according to RBC Capital Markets [3] Stock Performance - BDX's stock is currently priced at $180.62, reflecting an increase of 5.21% or $8.94, with fluctuations between a low of $170.67 and a high of $181.98 during the trading day [3] - Over the past year, BDX has reached a high of $185.02 and a low of $127.59, with a market capitalization of approximately $51.44 billion and a trading volume of 4,441,319 shares on the NYSE [3]

Core Insights - Becton, Dickinson and Company (BDX) has completed the spin-off of its Biosciences & Diagnostic business, merging it with Waters Corporation, marking the conclusion of a strategic transaction [1][8] Transaction Details - BD shareholders will receive 0.135 shares of Waters common stock for each BD share held as of February 5, 2026, with cash for any fractional shares [2] - BD received $4 billion in cash proceeds from the transaction, which will be allocated for share repurchases and debt reduction [6][10] Strategic Focus - The merger aligns with BD's 2025 strategy, positioning the company as a focused MedTech organization in response to healthcare trends [3][6] - BD has reshaped its portfolio by divesting non-core assets and making over 20 targeted acquisitions, enhancing its presence in high-growth healthcare segments [4][7] Market Performance - Following the announcement, BDX shares have declined by 17.2%, with a 10.8% decrease over the past six months, contrasting with industry growth of 26.7% and the S&P 500's 11.6% rise [5] Future Outlook - The completion of the transaction is expected to strengthen BD's strategic focus and enhance growth visibility, with plans to utilize the $4 billion proceeds for shareholder value creation [6][10] - BD aims to drive revenue expansion and improve cash flow by concentrating on connected medical devices, AI technologies, and chronic disease solutions [7][11]

2026年2月9日，医疗科技公司Becton, Dickinson and Company（BD）发布了其2026财年第一季度财报，尽管公司业绩超过华尔街预期，但股价在盘前交易中出现了 约4%的下跌，跌至 201.80美元 。 根据财报数据，BD第一季度的总营收为 52.5亿美元 （约合人民币 362亿 ） ， 同比增长 1.6% ，而 净利润 为 3.82亿美元 ，每股 收益为 1.34美元 。 # 业绩拆解：Q 1财 务数据超 出 预期，多项业务 表现 亮眼 BD第一季度的财报数据总体表现超出市场预期，尤其是在 调整后每股收益 （EPS）方面， 2.91美元 的结果较华尔街预期的 2.81美元 多出10美分。尽管整体营收增 长仅为1.6%，但各业务板块的增长表现则相对强劲，尤其是 Interventional （介入医疗）和 Connected Care （连接护理）两大核心业务。 整体来看，BD在大多数核心领域均保持稳定增长，尤其是在介入医疗和连接护理领域的表现非常强劲。不过，生命科学领域的下滑，部分反映了公司在该板块的战 略调整和市场环境变化。 # 战略与结构性 转型 ：分拆完成 ，迈向" N e w ...

Core Insights - Becton Dickinson reported first-quarter results that exceeded expectations, but the full-year profit outlook was significantly below analyst forecasts, leading to a more than 3% decline in shares [1] Financial Performance - The company posted adjusted earnings of $2.91 per share for the first quarter, surpassing analyst estimates of $2.81 [2] - Revenue increased by 1.6% year over year to $5.3 billion, exceeding the consensus estimate of $5.15 billion [2] - On a foreign-currency-neutral basis, revenue rose 0.4%, with New BD revenue growing 2.5% [2] Future Guidance - The fiscal 2026 adjusted earnings guidance is set at $12.35 to $12.65 per share, which is well below the analyst consensus of $14.94 [3] - This outlook reflects the impact of the combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation, which closed on the earnings release date [3] Segment Performance - The Connected Care segment led performance with a reported growth of 5.5%, or 4.7% on a foreign-currency-neutral basis [4] - The BD Interventional segment grew by 5.8% reported, or 5.1% FX-neutral [4] - The Life Sciences segment, which is being separated, declined by 8.3% reported and 10.5% on an FX-neutral basis [4] Revenue Outlook - Becton Dickinson reaffirmed its fiscal 2026 revenue growth outlook, expecting low-single-digit growth on a foreign-currency-neutral basis, with reported revenue growth anticipated in the "low single-digit plus" range [5]

Core Insights - BD reported earnings per share (EPS) of $2.91, exceeding estimates of $2.82, indicating strong financial performance in fiscal 2026 [2] - Revenue increased by 1.6% to $5.3 billion, surpassing the estimated $5.15 billion, with a foreign exchange-neutral revenue rise of 0.4% [2] - The merger with Waters Corporation aims to enhance shareholder value and is expected to contribute to gross margin expansion [3] Financial Performance - BD's price-to-earnings (P/E) ratio is approximately 35.87, indicating a premium investors are willing to pay for earnings [5] - The price-to-sales ratio stands at about 2.74, while the enterprise value to sales ratio is 3.58, reflecting the value placed on its sales [5] - The debt-to-equity ratio is approximately 0.76, suggesting a balanced approach to financing assets [5] Strategic Initiatives - The merger with Waters Corporation combines BD's Biosciences and Diagnostic Solutions business, focusing on innovation and productivity [3] - Tom Polen, BD's chairman and CEO, expressed confidence in the company's future prospects and affirmed revenue growth guidance for fiscal year 2026 [4]

FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025. "We delivered strongerthanexpected firstquarter performance which reflects our disciplined execution, including accelerated commercial initiatives and broadbased growth across key end markets," said Tom Polen, chairman, CEO and president of BD. "Today, we expect to complete the ...

Group 1: Company Overview - Becton, Dickinson and Company (NYSE:BDX) is an American multinational medical technology company that manufactures and sells essential medical devices and related products [5] Group 2: Financial Performance - In fiscal Q4 2025, Becton, Dickinson reported overall revenues of $5.9 billion, reflecting an 8.3% growth year-over-year [4] - The company reported cash and cash equivalents of $641 million and an operating cash flow of $3.4 billion in 2025 [4] - Becton returned $2.2 billion to investors through dividends and share repurchases, demonstrating its commitment to shareholder value [4] Group 3: Mergers and Acquisitions - The merger of Becton, Dickinson's Biosciences and Diagnostic Solutions, referred to as New BD, with Waters Corporation is expected to be completed around the end of the first quarter of 2026 [3] - New BD is projected to be a significant MedTech company with a broad impact on patients and healthcare globally [3] Group 4: Analyst Insights - Morgan Stanley analyst Patrick Wood raised the price target for Becton, Dickinson to $210 from $197, maintaining an Overweight rating, citing a positive outlook for the MedTech sector [2] - The analyst noted that major product cycles, healthier hospital spending, and low valuations indicate a supportive environment for the industry in the upcoming year [2] Group 5: Revenue Growth - New BD reported revenue of $17.5 billion in FY25, an increase from $16.8 billion in the previous year [3]

Core Insights - Solventum has appointed Heather Knight as Chief Commercial Officer, effective November 10, 2025, to oversee global commercial and R&D operations across its MedSurg, Dental Solutions, and Health Information Systems segments [1][3] - Ms. Knight has over 30 years of leadership experience in the MedTech industry, previously serving as COO at Baxter International and holding various leadership roles at Medtronic, Covidien, Tyco Healthcare, and Kendall [2] - The appointment aims to enhance Solventum's go-to-market strategy and drive profitable growth as the company transitions into a standalone entity [3] Company Strategy - The appointment of Ms. Knight reflects Solventum's commitment to building a high-performing organization and progressing towards becoming a leading global MedTech company [3] - The alignment of the go-to-market strategy under one leader is expected to improve coordinated execution and leverage the company's size and scale [3] - Ms. Knight expressed enthusiasm about joining Solventum during a pivotal time in the execution of the company's multi-year strategic plan [3] Leadership Changes - Chris Barry, the Executive Vice President and Group President of MedSurg, will depart Solventum effective December 31, 2025, following Ms. Knight's appointment [3][4] - Mr. Hanson acknowledged Chris Barry's contributions and leadership in the MedSurg segment, ensuring a seamless transition [4] Financial Guidance - The leadership change does not impact Solventum's financial guidance, with the next update expected during the third quarter results announcement in early November [4]

Core Insights - Becton, Dickinson and Co. (BDX) is a multinational medical technology company focused on manufacturing and selling medical devices, instruments, and reagents globally [1] Financial Performance - The company is set to report its Q4 2025 earnings on November 6, with analysts expecting an EPS of $3.92, an increase from $3.81 in the prior year [2] - Quarterly revenue is anticipated to reach $5.92 billion, up from $5.44 billion a year earlier [2] - In Q3 2025, Becton Dickinson reported an adjusted EPS of $3.68, exceeding the consensus estimate of $3.41, and revenues of $5.51 billion, slightly above the consensus of $5.49 billion [3] Growth and Strategic Initiatives - The CEO highlighted an increase in organic growth trajectory in Q3, along with strong margin and EPS growth, which led to a raised EPS guidance for the full year [4] - The full-year 2025 adjusted EPS guidance has been raised to a range of $14.30 to $14.45, reflecting a $0.18 increase and a 9.4% growth at the midpoint [4] - An agreement was announced to combine BD's Biosciences and Diagnostic Solutions business with Waters Corporation, aimed at creating a leader in life sciences and diagnostics focused on high-volume testing [4]